Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Sequoia China Investment Management
Pharma
BeiGene-Novartis, China's VBP and more—Fierce Pharma Asia
BeiGene and Novartis' PD-1 got delayed at the FDA. China cuts drug prices again to Big Pharma's detriment. A Pfizer partner reportedly explores sale.
Angus Liu
Jul 15, 2022 10:38am
FiercePharmaAsia—WuXi, SinoBioway, Takeda and more
May 18, 2018 9:10am
FiercePharmaAsia—China's landmark nod, Samsung, WuXi and more
May 4, 2018 9:56am
FiercePharmaAsia—Takeda, Shanghai Pharma, WuXi NextCODE
Jan 26, 2018 9:37am
